News Conference News ESC 2024 Trial Challenges Continuation of Oral Anticoagulants During TAVI Todd Neale August 31, 2024
News Conference News ESC 2022 INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF Michael O'Riordan August 28, 2022
News Conference News ESC 2022 Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke Todd Neale August 28, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Conference News ESC 2020 Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism Caitlin E. Cox September 04, 2020
News Conference News ESC 2018 MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis Todd Neale August 26, 2018
News Conference News ESC 2017 IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib Todd Neale August 30, 2017
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017
News Conference News ESC 2016 Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4 Todd Neale August 31, 2016
News Conference News ESC 2016 NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry Michael O'Riordan August 28, 2016
News Conference News ESC 2012 WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants Yael L. Maxwell August 28, 2012
News Conference News RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets August 31, 2011